Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1

Extracellular vesicles (EVs) carrying tumor cell-derived programmed death-ligand 1 (PD-L1) interact with programmed death 1 (PD-1)-producing T cells, thus significantly lowering a patient's response to immune checkpoint blockade drugs. No drug that reinvigorates CD8+ T cells by suppressing EV P...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chan-Hyeong, Bae, Ju-Hyun, Choe, Eun-Ji, Park, Ju-Mi, Park, Seong-Sik, Cho, Hee Jin, Song, Byoung-Joon, Baek, Moon-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899590/
https://www.ncbi.nlm.nih.gov/pubmed/35265193
http://dx.doi.org/10.7150/thno.68864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899590/
https://www.ncbi.nlm.nih.gov/pubmed/35265193
http://dx.doi.org/10.7150/thno.68864

Ejemplares similares